Novel Regulation of Beta Andregenic Receptor Function
Novel Regulation of Beta Andregenic Receptor Function
批准号:
8630940
负责人:
Sathyamangla V Prasad
金额:
$39.63万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-04-01 至 2017-11-30
关键词:
ADRBK1 geneAddressAdenovirus VectorAdrenergic ReceptorAdultAgonistArrestinsBackBeliefBindingCardiacCatecholaminesCell membraneChronicCouplingDissociationDown-RegulationEmbryoEndocytosisEndosomesEventFibroblastsFunctional disorderFundingGTP-Binding ProteinsGoalsHeartHeart HypertrophyHeart failureHomeostasisIn VitroInflammatoryInfusion proceduresIsoproterenolKnockout MiceLeadMainstreamingMapsMediatingMolecularMusMuscle CellsPathway interactionsPeptidesPharmaceutical PreparationsPhosphatidylinositolsPhosphorylationPhosphotransferasesPlasmaPlayProcessProtein DephosphorylationProtein phosphataseProteinsRecyclingRegulationResearchRoleSET geneSerineSignal TransductionStressSurfaceTNF geneTestingTransgenic MiceTumor Necrosis Factor Receptorbaseconstrictioncytokinedesensitizationin vivoinhibitor/antagonistmouse modelmutantnew therapeutic targetnovelnovel therapeuticsoverexpressionpreventpublic health relevancereceptorreceptor functionresearch studyresponse
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
b-adrenergic receptors (bARs) are one of the powerful regulators of cardiac function. bAR downregulation
(loss of surface receptors) and desensitization (impaired G-protein coupling) are hallmarks of a failing heart.
Desensitization is initiated by phosphorylation of bARs by bAR kinase 1 (bARK1 or GRK2) in response to
catecholamines resulting in reduced cardiac responses. b-arrestin binds phosphorylated bARs facilitating
their endocytosis (downregulation). Phosphorylated bARs are resensitized by dephosphorylation mediated
through protein phosphatase 2A (PP2A) in the endosomes and are recycled back to the plasma membrane
as na¿ve receptor ready for activation. Contrary to the belief that resensitization is a process that maintains
homeostasis, our mechanistic studies in the current RO1 have identified that PI3Kg inhibits PP2A activity,
thereby negatively regulating bAR resensitization. We have shown that PI3Kg phosphorylates endogenous
inhibitor of PP2A (I2PP2A) on serine 9 & 93 (S9, 93) that robustly binds to PP2A, inhibiting PP2A activity and
blocking bAR resensitization, effectively determining that the PI3Kg-I2PP2A-PP2A pathway regulates bAR
resensitization. Although we have identified the pathway that regulates bAR resensitization, it is not known
whether this pathway is altered and contributes to cardiac hypertrophy and heart failure. Therefore, the goal
of the renewal is to determine whether the resensitization pathway is altered in conditions of heart failure and
test whether targeting components of resensitization using genetically altered mice could provide beneficial
remodeling upon stress. We have generated transgenic mice with cardiac overexpression of wild type
I2PP2A (Wt I2PP2A Tg) or I2PP2A mutants S9, 93A (I2PP2A S9, 93A Tg, mimicking dephospho state) or
S9, 93D (I2PP2A S9, 93D Tg, phospho state). Our preliminary studies show that subjecting Wt I2PP2A Tg
mice or I2PP2A S9, 93D Tg mice to cardiac stress results in accelerated cardiac dysfunction which is
markedly ameliorated in I2PP2A S9, 93A Tg mice suggesting a critical role for bAR resensitization in
deleterious remodeling. Additionally, we also observed non-classical Gbg-independent PI3Kg recruitment to
bARs in response to pro-inflammatory cytokine TNFa which may inhibit PP2A activity leading to loss in bAR
resensitization suggesting that TNFa could regulate bAR function by altering the PI3Kg-I2PP2A-PP2A axis.
Based on these preliminary studies, we hypothesize that bAR resensitization is inhibited by the PI3Kg-
I2PP2A-PP2A pathway upon cardiac stress and releasing the inhibition on bAR resensitization by targeting
I2PP2A could preserve bAR function and prevent deleterious cardiac remodeling. We propose the following
specific aims to address the hypothesis: Specific aim 1: To determine whether regulating cardiac bAR
resensitization pathway prevents deleterious cardiac remodeling in response to cardiac stress, Specific aim
2: To identify the molecular basis of PI3Kg mediated I2PP2A-PP2A interaction and its role in bAR
resensitization, Specific aim 3: To investigate the molecular mechanisms mediating agonist independent
non-canonical recruitment of PI3Kg and inhibition of bAR resensitization in response to TNFa. Determining
the role of PI3Kg-I2PP2A-PP2A axis in regulating bAR resensitization in response to cardiac stress will
provide comprehensive mechanistic understanding of bAR dysfunction leading to identification of novel
therapeutic strategies for heart failure by targeting bAR resensitization pathway.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinase
-
批准号:10591688
-
项目类别:
-
资助金额:$63.77万
-
财政年份:2022
-
负责人:Sathyamangla V Prasad
-
依托单位:
Non-canonical regulation of GRK2 by TNFalpha impairs BetaAR function
-
批准号:9243307
-
项目类别:
-
资助金额:$39.63万
-
财政年份:2016
-
负责人:Sathyamangla V Prasad
-
依托单位:
Beta adrenergic receptor resensitization in asthma
-
批准号:9205534
-
项目类别:
-
资助金额:$39.63万
-
财政年份:2016
-
负责人:Sathyamangla V Prasad
-
依托单位:
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinas
-
批准号:7839075
-
项目类别:
-
资助金额:$23.48万
-
财政年份:2009
-
负责人:Sathyamangla V Prasad
-
依托单位:
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinas
-
批准号:8064318
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2008
-
负责人:Sathyamangla V Prasad
-
依托单位:
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinas
-
批准号:7600496
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2008
-
负责人:Sathyamangla V Prasad
-
依托单位:
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinas
-
批准号:8236869
-
项目类别:
-
资助金额:$38.24万
-
财政年份:2008
-
负责人:Sathyamangla V Prasad
-
依托单位:
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinas
-
批准号:7456671
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2008
-
负责人:Sathyamangla V Prasad
-
依托单位:
Novel regulation of beta-adrenergic receptor function by phosphoinositide 3-kinas
-
批准号:7792377
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2008
-
负责人:Sathyamangla V Prasad
-
依托单位:
海外基金